RT @epocrates: Early triple antiviral therapy shows promise in COVID-19. https://t.co/qEDtIeP0hS https://t.co/TfachRTZ5P
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @DrSamuelBrown: Finally was able to read the IFN trial--https://t.co/Chh6crUwkr . Fascinating. It honestly does look like IFN has an eff…
RT @DrSamuelBrown: Finally was able to read the IFN trial--https://t.co/Chh6crUwkr . Fascinating. It honestly does look like IFN has an eff…
Triple antiviral therapy for COVID-19 shows some promise. We need a vaccine, accurate and accessible testing, and antiviral treatment. https://t.co/DRKxk4Z1G7
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/45dyGtSjeL
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
Early triple antiviral therapy shows promise in COVID-19. https://t.co/qEDtIeP0hS https://t.co/TfachRTZ5P
Early triple antiviral therapy shows promise in COVID-19 https://t.co/SFMW8W65DP Shared from Epocrates, The #1 medical reference app. https://t.co/6B3jbzYYWk https://t.co/YrXS20ILnY
RT @DrSamuelBrown: Finally was able to read the IFN trial--https://t.co/Chh6crUwkr . Fascinating. It honestly does look like IFN has an eff…
RT @DrSamuelBrown: Finally was able to read the IFN trial--https://t.co/Chh6crUwkr . Fascinating. It honestly does look like IFN has an eff…
Finally was able to read the IFN trial--https://t.co/Chh6crUwkr . Fascinating. It honestly does look like IFN has an effect. Crucially, these patients look like they are mostly the equivalent of US outpatients, and the main effect is in movement from at mo
RT @EricTopol: Very encouraging randomized trial results for interferon β-1b in mild to moderate #COVID19: marked reduction viral shedding,…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
Promissor! Combinação tripla de interferon beta-1b, lopinavir – ritonavir e ribavirina no tratamento de pacientes internados no hospital com COVID-19. https://t.co/OKArFJdVqK
@jsherkow @RESachs @PatentScholar @WNicholsonPrice Also adding interferon beta 1b to a protease inhibitor appears to be useful https://t.co/x6ZG2NYrGB
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
La combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina reduce los síntomas, diseminación viral y tiempo de hospitalización. En 7 días ya no se detecta el virus. https://t.co/Yi8fPCZUnG https://t.co/HfViL8Idao https://t.co/NRKd9LTxV0
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin seems to be an effective antiviral therapy to fight covid19 https://t.co/zRh3Tl0jNS
RT @InternosPy: 🚨🆕 Triple combinación de interferón beta-1b, lopinavir-ritonavir y ribavirina en el tratamiento de pacientes ingresados e…
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19. Interpretation: Early triple antiviral therapy was safe and superior to lopinavir–ritona…https://t.co/FIkpwnUtKS
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
COVID-19 CORONAVIRUS DISEASE PANDEMIC / RESEARCH INTO DRUG TREATMENTS FOR COVID-19 CORONAVIRUS DISEASE: https://t.co/Ampfkc3gaS
RT @nathanpsmad: 🔥Interesting #RCT for #COVID19 #SARS_CoV_2 Interferon beta-1b, lopinavir–ritonavir, ribavirin in MILD patients (0 death,…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @hjellebrian1: Somewhat promising 4-drug trial involving B-IFN, lopinovir/ritonavir and ribavirin. The active ingredient was likely the…
Somewhat promising 4-drug trial involving B-IFN, lopinovir/ritonavir and ribavirin. The active ingredient was likely the B-IFN. Lopinovir/ritonavir already has failed on its own, and the error crises induced by ribavirin likely spare nCoV. https://t.co/F
RT @jcperezpons: Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hosp…
RT @jcperezpons: Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hosp…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/1On1iLnqhp
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/9w5YxjyvPT
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with #COVID-19. https://t.co/CDGgY9IjEi
Recent work in Lancet shows efficacy of recombinant cytokine IFNbeta in Covid-19. We produce recombinant chemokines and cytokines for use in SARS-CoV2 and related biomedical research. #research #Covid19. Discover more here! https://t.co/DK6dtNoNFS https:
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
Always great to hear from the authors themselves: Dr. Hung talking about his recent paper on lopinavir/r + interferon + ribavirin (https://t.co/XySlCdBfoh) #COVID19 https://t.co/9lteWwWHzM
RT @internistaneumo: interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients with COVID-19 🙈
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
Una luz ante Covid-19...😊⚗️🔬 https://t.co/D4pJzFVKCg
RT @lucavalenti75: back to ifn+rbv? https://t.co/jgtVYv6KPO
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
@danieljadue 👀👇🏼🤓
Adverse effects/costs vs benefits. Probably not justifiable in current study population. https://t.co/ctxeHmeTrk
@__Verlaine__ @raoult_didier Faux. L'IFN a très probablement sauvé des vies. Or bloquer les voies IFN avec de l'hcq est à prendre en considération dans la balance bénef risque globale. https://t.co/IFHUBwgmMu
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
RT @kj26csi: インターフェロンや抗ウイルス薬の3剤併用療法の治験結果。 特に早期(発症から4,5日)の適用が奏功する。 ウイルスが検出されなくなるまでの日数が、対照群12日に対して7日と統計的有意に短縮されたと。 ただしトータル死者ゼロの治験で、重症例や死亡率への…
インターフェロンや抗ウイルス薬の3剤併用療法の治験結果。 特に早期(発症から4,5日)の適用が奏功する。 ウイルスが検出されなくなるまでの日数が、対照群12日に対して7日と統計的有意に短縮されたと。 ただしトータル死者ゼロの治験で、重症例や死亡率への影響は不明。 https://t.co/4Kg5HbT2mY
RT @richardhorton1: Important early new data on combination treatment for mild-moderate COVID-19. Extremely encouraging.
RT @EricTopol: Very encouraging randomized trial results for interferon β-1b in mild to moderate #COVID19: marked reduction viral shedding,…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @reSearchAndDes1: Cold take: In a sample of ppl who are PCR+ for SARS-CoV-2 but not actually ill, 4-drug combination antiviral therapy a…
Espoir: un essai randomisé. Test pendant 14 jours une combinaison lopinavir 400 mg + ritonavir 100 mg/12 h + ribavirin 400 mg/12 h + 8 million d'unités internationales d'interferon beta-1b vs ritonavir 100 mg every 12 h (groupe contrôle). https://t.co/Tma8
Cold take: In a sample of ppl who are PCR+ for SARS-CoV-2 but not actually ill, 4-drug combination antiviral therapy appears to reduce viral load. https://t.co/Rq21ovI00s
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
@LuisZuritaG Doc, estos medicamentos se consiguen aca? Y como seria su administracion, agradeceria su respuesta.
RT @Paulakyn: Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospita…
RT @AndyBiotech: #COVID19 Hopeful data of the day Triple combo of interferon beta-1b + ribavirin + Kaletra shown to be superior to Kaletra…
RT @srrezaie: Triple therapy with interferon beta-1b, lopinavir-ritonavir, & ribavirin used early in illness shortened virus shedding, alle…
RT @AndyBiotech: #COVID19 Hopeful data of the day Triple combo of interferon beta-1b + ribavirin + Kaletra shown to be superior to Kaletra…
RT @juanitoanaconda: Interferon Beta 1b, Lopinavir-Ritonavir, ribavirina levantan grandes espectativas. https://t.co/gwOc7YiCMY
RT @influenzer3: ●昨日、新聞記事で紹介した3剤併用療法について →RBV+ IFN-β-1b+LPV/rの3剤併用とLPV/r単剤とのRCT。 併用群がウイルス量を有意に減らし、臨床症状を改善させ、IL-6を低下させたという結果です。 副作用がLPV/r単剤と…
Interferon Beta 1b, Lopinavir-Ritonavir, ribavirina levantan grandes espectativas. https://t.co/gwOc7YiCMY
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/C1g3m5Hny5
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
👏🏽👏🏽👏🏽👏🏽👏🏽
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
RT @EmilioAlegre1: ECA fase2 triple terapia (L/r+RBV+IFN-B sc) vs. L/r en 162 vs 81 pacientes PCR+ hospitalizados. Pero en Hong Kong, donde…
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
RT @nathanpsmad: Les traitements de #DisCoVeRY plus que jamais d'actualité : seul essai académique qui teste le #remdesivir en #Europe et p…
RT @EmilioAlegre1: ECA fase2 triple terapia (L/r+RBV+IFN-B sc) vs. L/r en 162 vs 81 pacientes PCR+ hospitalizados. Pero en Hong Kong, donde…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - The Lancet https://t.co/InEB44vcbS
@alex_seibar88 Det börjar komma en del studier som faktiskt visar på att man kan behandla Covid19. https://t.co/mbacRheekD
Some light at the end of the tunnel? 🤞🤞. This antiviral cocktail seems promising..#COVID19 #Covid_19 #covidtreatment #coronavirus #coronatreatment #treatment https://t.co/4rkvU5sfSo
THIS: https://t.co/ElSeGa09r2 was open label, only on 127 patients w/mild 2 moderate symptoms, but shed 5 days ( fm 12 to 7) to undetectable. Not a panacea, but in good supply all drugs, if it can be replicated double blind larger cohort, significant impro
RT @gorka_orive: Un ensayo clínico reciente demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tra…
RT @campaignstrat: @normanlamb
3-Combo IFN b-1b, lopinavir–ritonavir & ribavirin vs latter 2 (control), in mil-mod covid19, showed earlier viral swab neg (primary end pt) + symptom resolution, less hosp LOS. Open label, multi-centred RCT. Phase 2 trial, but hopeful https://t.co/lhQ
RT @nathanpsmad: 🔥Interesting #RCT for #COVID19 #SARS_CoV_2 Interferon beta-1b, lopinavir–ritonavir, ribavirin in MILD patients (0 death,…